anurajms/meta_analysis huggingface dataset:
Provide patient population that should be included in the study
Complete versus culprit‐only revascularisation in ST elevation myocardial infarction with multi‐vessel disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Acute St Segment Elevation Myocardial Infarction 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nitric oxide donors (nitrates), L‐arginine, or nitric oxide synthase inhibitors for acute stroke
1. Aged 80 and over 80+ years 2. Intracerebral Hemorrhage 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Ischemic Stroke 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Atrial Fibrillation 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ischemic Stroke 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise‐based cardiac rehabilitation in heart transplant recipients
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Heart Transplant 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non‐asphyxial out‐of‐hospital cardiac arrest
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Cardiac Arrest 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Vitamin C supplementation for the primary prevention of cardiovascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Risk scoring for the primary prevention of cardiovascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Eplerenone for hypertension
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Essential Hypertension 6. Aged 65-79 years
Provide patient population that should be included in the study
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Thromboembolism 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Ranolazine for stable angina pectoris
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Angina Pectoris 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta‐blockers for hypertension
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Essential Hypertension 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Abdominal Aortic Aneurysm 6. Aged 65-79 years
Provide patient population that should be included in the study
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Ischaemic Heart Disease 8. Coronary Heart Disease 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Caregiver‐mediated exercises for improving outcomes after stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure‐lowering efficacy of reserpine for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions to improve adherence to lipid‐lowering medication
1. Aged 80 and over 80+ years 2. Patient On Self-medication 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Oxygen therapy for acute myocardial infarction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Acute Myocardial Infarction
Provide patient population that should be included in the study
Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Varicose Veins Of Leg With Short Saphenous Vein Distribution 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Efficacy and safety of ablation for people with non‐paroxysmal atrial fibrillation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Atrial Fibrillation 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrates for primary prevention of cardiovascular disease events
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. At Risk Of Disease 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Deep Venous Thrombosis
Provide patient population that should be included in the study
Pharmacological interventions other than botulinum toxin for spasticity after stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Spasticity 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Heart Failure 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Self management programmes for quality of life in people with stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports
1. Aged 80 and over 80+ years 2. Insertion Of Implantable Venous Access Port 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Intravenous heparin during ruptured abdominal aortic aneurysmal repair
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Ruptured Abdominal Aortic Aneurysm
Provide patient population that should be included in the study
Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Peripheral Arterial Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Chagas' Disease With Heart Involvement 5. Young Adult 19-24 years 6. Heart Failure 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Sulodexide for treating venous leg ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Venous leg ulcer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Routine invasive strategies versus selective invasive strategies for unstable angina and non‐ST elevation myocardial infarction in the stent era
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Angina Attack 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Syncope 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Child 6-12 years 4. Total knee arthroplasty 5. Infant 1 to 23 mo 6. Aged 65-79 years 7. Adolescent 13-18 years 8. Adult 19-44 years 9. Middle Aged 45-64 years 10. Young Adult 19-24 years 11. Total hip replacement 12. Birth to 1 mo 13. Hip Fracture Repair
Provide patient population that should be included in the study
Pre‐hospital versus in‐hospital initiation of cooling for survival and neuroprotection after out‐of‐hospital cardiac arrest
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiac Arrest 6. Aged 65-79 years
Provide patient population that should be included in the study
Blood pressure lowering efficacy of beta‐1 selective beta blockers for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Essential Hypertension 6. Aged 65-79 years
Provide patient population that should be included in the study
Interventions for helping people adhere to compression treatments for venous leg ulceration
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Venous leg ulcer
Provide patient population that should be included in the study
Calcium channel blockers for primary Raynaud's phenomenon
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Raynaud's Phenomenon 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Sexual counselling for sexual problems in patients with cardiovascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Congenital Heart Disease 4. Myocardial Infarction 5. Middle Aged 45-64 years 6. Heart disease 7. Angina Pectoris 8. Young Adult 19-24 years 9. Heart Failure 10. Coronary Revascularisation 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Oral aspirin for treating venous leg ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Venous leg ulcer
Provide patient population that should be included in the study
Biphasic versus monophasic waveforms for transthoracic defibrillation in out‐of‐hospital cardiac arrest
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiac Arrest 6. Ventricular Fibrillation 7. Aged 65-79 years 8. Ventricular Tachycardia
Provide patient population that should be included in the study
Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Healthy 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Warfarin initiation nomograms for venous thromboembolism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Acute Pulmonary Thromboembolism 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. General Anesthesia 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Colchicine for prevention of cardiovascular events
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Diseases and disorders 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Venous leg ulcer
Provide patient population that should be included in the study
Internet‐based interventions for the secondary prevention of coronary heart disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Coronary Heart Disease 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Heart Failure With Reduced Ejection Fraction 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. At Risk Of Disease 6. Left Ventricular Abnormality 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Aminophylline for bradyasystolic cardiac arrest in adults
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiac Arrest 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Structured telephone support or non‐invasive telemonitoring for patients with heart failure
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Heart Failure 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Fibrates for secondary prevention of cardiovascular disease and stroke
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Stroke 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Coronary Heart Disease 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Implantable defibrillators versus medical therapy for cardiac channelopathies
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Short QT Syndrome 6. Catecholaminergic Polymorphic Ventricular Tachycardia 7. Aged 65-79 years 8. Brugada Syndrome 9. Adolescent 13-18 years 10. Congenital long QT syndrome
Provide patient population that should be included in the study
Stent graft types for endovascular repair of thoracic aortic aneurysms
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Thoracoabdominal Aortic Aneurysm 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Debridement for venous leg ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Venous leg ulcer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Cryptogenic Stroke 5. Patent Foramen Ovale 6. Young Adult 19-24 years 7. Aged 65-79 years 8. Adolescent 13-18 years 9. Transient Cerebral Ischemia
Provide patient population that should be included in the study
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Prophylactic lidocaine for myocardial infarction
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years 7. Acute Myocardial Infarction
Provide patient population that should be included in the study
Buflomedil for acute ischaemic stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ischemic Stroke 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Negative pressure wound therapy for treating leg ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Leg Ulcer 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Fresh frozen plasma for cardiovascular surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Surgery 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychosocial interventions for smoking cessation in patients with coronary heart disease
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Smoker 8. Coronary Heart Disease 9. Young Adult 19-24 years 10. Birth to 1 mo 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for post‐stroke fatigue
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Psychological interventions for symptomatic management of non‐specific chest pain in patients with normal coronary anatomy
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Chest Pain 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Cardiac surgery 5. Thoracic Surgery
Provide patient population that should be included in the study
Motivational interviewing for improving recovery after stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Anti‐inflammatory treatment for carditis in acute rheumatic fever
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Heart disease 7. Young Adult 19-24 years 8. Rheumatic Fever 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure‐lowering efficacy of loop diuretics for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years 12. Raised Serum Creatinine
Provide patient population that should be included in the study
Adenosine and verapamil for no‐reflow during primary percutaneous coronary intervention in people with acute myocardial infarction
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years 11. Acute Myocardial Infarction
Provide patient population that should be included in the study
Influenza vaccines for preventing cardiovascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Intra‐aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Myocardial Infarction 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Cardiogenic Shock 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Anaesthetic and sedative agents used for electrical cardioversion
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Direct Current Cardioversion 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for improving community ambulation in individuals with stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Atorvastatin for lowering lipids
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Cardiopulmonary Bypass
Provide patient population that should be included in the study
Transmyocardial laser revascularization versus medical therapy for refractory angina
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Angina Pectoris 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Bypass Surgery 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Sinus Rhythm 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta‐adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Surgery 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Statins for primary prevention of venous thromboembolism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Biologics, colchicine, corticosteroids, immunosuppressants and interferon‐alpha for Neuro‐Behçet's Syndrome
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Neuro-Behcet Syndrome 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Renal Hypertension 6. Aged 65-79 years
Provide patient population that should be included in the study
Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Rosuvastatin for lowering lipids
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Interventions for deliberately altering blood pressure in acute stroke
1. Aged 80 and over 80+ years 2. Intracerebral Hemorrhage 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Ischemic Stroke 7. Aged 65-79 years
Provide patient population that should be included in the study
Cardiopulmonary resuscitation (CPR) plus delayed defibrillation versus immediate defibrillation for out‐of‐hospital cardiac arrest
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiac Arrest 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Pre‐hospital versus in‐hospital thrombolysis for ST‐elevation myocardial infarction
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Acute St Segment Elevation Myocardial Infarction 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Time course for blood pressure lowering of dihydropyridine calcium channel blockers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Hypertensive disorder
Provide patient population that should be included in the study
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Exercise for people with high cardiovascular risk
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Cardiovascular Event Risk 6. Aged 65-79 years
Provide patient population that should be included in the study
Heparin versus placebo for non‐ST elevation acute coronary syndromes
1. Aged 80 and over 80+ years 2. Acute Non-st Segment Elevation Myocardial Infarction 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Acute Coronary Syndrome
Provide patient population that should be included in the study
Angioplasty versus bare metal stenting for superficial femoral artery lesions
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Superficial Femoral Artery Stenosis 6. Aged 65-79 years
Provide patient population that should be included in the study
Anticoagulation therapy versus placebo for pulmonary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Pulmonary Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure‐lowering efficacy of monotherapy with thiazide diuretics for primary hypertension
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Essential Hypertension 6. Aged 65-79 years 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Trypanosoma Cruzi infection 6. Aged 65-79 years
Provide patient population that should be included in the study
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intermittent claudication 6. Aged 65-79 years
Provide patient population that should be included in the study
Type of incision for below knee amputation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Lower Limb Ischemia
Provide patient population that should be included in the study
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke
1. Stroke
Provide patient population that should be included in the study
Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Young Adult 19-24 years 7. Solid Organ Transplant 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Combined oral contraceptives: venous thrombosis
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Oral Contraception 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure lowering efficacy of nonselective beta‐blockers for primary hypertension
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Essential Hypertension 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
First‐line beta‐blockers versus other antihypertensive medications for chronic type B aortic dissection
1. Aged 80 and over 80+ years 2. Type B Aortic Dissection 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Insulin for glycaemic control in acute ischaemic stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Ischemic Stroke 6. Aged 65-79 years
Provide patient population that should be included in the study
Endovascular repair of abdominal aortic aneurysm
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Abdominal Aortic Aneurysm 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics and antiseptics for venous leg ulcers
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Venous leg ulcer 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
Intravascular brachytherapy for peripheral vascular disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Peripheral Vascular Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Treatment of hypertension in peripheral arterial disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Peripheral Arterial Disease 6. Aged 65-79 years 7. Hypertensive disorder 8. Multiple chronic conditions
Provide patient population that should be included in the study
Immunosuppressive T‐cell antibody induction for heart transplant recipients
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Heart Transplant 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Blood pressure targets for hypertension in people with diabetes mellitus
1. Diabetes Mellitus 2. Hypertensive disorder
Provide patient population that should be included in the study
Corticosteroids for viral myocarditis
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Viral Myocarditis 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Beta blockers for peripheral arterial disease
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Peripheral Arterial Disease 6. Aged 65-79 years
Provide patient population that should be included in the study
Nitrates for acute heart failure syndromes
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Acute Heart Failure Syndrome
Provide patient population that should be included in the study
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pulmonary Embolism 6. Aged 65-79 years 7. Deep Venous Thrombosis
Provide patient population that should be included in the study
Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post‐stroke spasticity
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Spasticity As Sequela Of Stroke 6. Aged 65-79 years
Provide patient population that should be included in the study
Occupational therapy for care home residents with stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Early versus delayed mobilisation for aneurysmal subarachnoid haemorrhage
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Aneurysmal subarachnoid hemorrhage
Provide patient population that should be included in the study
Continuous versus intermittent physiological monitoring for acute stroke
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years
Provide patient population that should be included in the study
Flavonoids for treating venous leg ulcers
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Venous leg ulcer 6. Aged 65-79 years
Provide patient population that should be included in the study
Cholesterol‐reducing agents for aneurysmal subarachnoid haemorrhage
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Aged 65-79 years 6. Aneurysmal subarachnoid hemorrhage
Provide patient population that should be included in the study
Non‐pharmacological interventions for preventing secondary vascular events after stroke or transient ischemic attack
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Stroke 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years 7. Transient Cerebral Ischemia
Provide patient population that should be included in the study
Physical rehabilitation for older people in long‐term care
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years 4. Living In Nursing Home
Provide patient population that should be included in the study
Hypothermia for neuroprotection in children after cardiopulmonary arrest
1. Child, Preschool 2-5 years 2. Cardiorespiratory Arrest 3. Child 6-12 years 4. Infant 1 to 23 mo 5. Birth to 1 mo 6. Resuscitation 7. Adolescent 13-18 years
Provide patient population that should be included in the study
Wolbachia‐carrying Aedes mosquitoes for preventing dengue infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Dengue endemic area 7. Young Adult 19-24 years 8. Aged 65-79 years 9. Adolescent 13-18 years
Provide patient population that should be included in the study
Vaccines for preventing herpes zoster in older adults
1. Aged 80 and over 80+ years 2. Middle Aged 45-64 years 3. Aged 65-79 years
Provide patient population that should be included in the study
Antiplatelet agents for the treatment of adults with COVID‐19
1. Aged 80 and over 80+ years 2. COVID-19 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children
1. Acute Diarrhea 2. Severe Dehydration 3. Birth to 1 mo
Provide patient population that should be included in the study
Therapeutics for treating mpox in humans
1. Mpox
Provide patient population that should be included in the study
Hyperimmune immunoglobulin for people with COVID‐19
1. Aged 80 and over 80+ years 2. COVID-19 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Remdesivir for the treatment of COVID‐19
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Exposure to COVID-19 6. Aged 65-79 years
Provide patient population that should be included in the study
Systemic corticosteroids for the treatment of COVID‐19: Equity‐related analyses and update on evidence
1. Aged 80 and over 80+ years 2. COVID-19 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Ivermectin for preventing and treating COVID‐19
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. COVID-19 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Aged 65-79 years 11. Healthy 12. Adolescent 13-18 years
Provide patient population that should be included in the study
SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Young Adult 19-24 years 8. Birth to 1 mo 9. Aged 65-79 years 10. Adolescent 13-18 years
Provide patient population that should be included in the study
Janus kinase inhibitors for the treatment of COVID‐19
1. COVID-19 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years
Provide patient population that should be included in the study
Inhaled corticosteroids for the treatment of COVID‐19
1. COVID-19
Provide patient population that should be included in the study
Antibiotics for the treatment of COVID‐19
1. Aged 80 and over 80+ years 2. COVID-19 3. Adult 19-44 years 4. Middle Aged 45-64 years 5. Young Adult 19-24 years 6. Aged 65-79 years
Provide patient population that should be included in the study
Colchicine for the treatment of COVID‐19
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. COVID-19 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Young Adult 19-24 years 8. Hospitalization 9. SARS-CoV-2 Virus 10. Aged 65-79 years 11. Adolescent 13-18 years
Provide patient population that should be included in the study
SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
1. COVID-19
Provide patient population that should be included in the study
Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Tuberculosis 5. Young Adult 19-24 years 6. HIV infection 7. Aged 65-79 years 8. Adolescent 13-18 years
Provide patient population that should be included in the study
Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Benign prostatic hyperplasia 5. Lower urinary tract symptoms 6. Aged 65-79 years
Provide patient population that should be included in the study
Effect of mass deworming with antihelminthics for soil‐transmitted helminths during pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Second Trimester Pregnancy 4. Young Adult 19-24 years 5. Third Trimester Pregnancy 6. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical microbicides for preventing sexually transmitted infections
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Sexually Active With Men 5. Adolescent 13-18 years
Provide patient population that should be included in the study
Topical antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving mechanical ventilation
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Intensive Care 6. Mechanical ventilation 7. Aged 65-79 years
Provide patient population that should be included in the study
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID‐19 infection
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. Adult 19-44 years 4. Child 6-12 years 5. Middle Aged 45-64 years 6. Infant 1 to 23 mo 7. Healthcare Professional 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Exposure to COVID-19 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Antimicrobial mouthwashes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID‐19 infection to improve patient outcomes and to protect healthcare workers treating them
1. Child, Preschool 2-5 years 2. Aged 80 and over 80+ years 3. COVID-19 4. Adult 19-44 years 5. Child 6-12 years 6. Middle Aged 45-64 years 7. Infant 1 to 23 mo 8. Young Adult 19-24 years 9. Birth to 1 mo 10. Suspected COVID-19 11. Aged 65-79 years 12. Adolescent 13-18 years
Provide patient population that should be included in the study
Video calls for reducing social isolation and loneliness in older people: a rapid review
1. Aged 80 and over 80+ years 2. Aged 65-79 years
Provide patient population that should be included in the study
Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
1. Aged 80 and over 80+ years 2. Adult 19-44 years 3. Middle Aged 45-64 years 4. Young Adult 19-24 years 5. Pulmonary Tuberculosis 6. Aged 65-79 years
Provide patient population that should be included in the study
Antibiotics for asymptomatic bacteriuria in pregnancy
1. Adult 19-44 years 2. Middle Aged 45-64 years 3. Young Adult 19-24 years 4. Pregnancy 5. Asymptomatic Bacteriuria 6. Adolescent 13-18 years